BIAL’s Post

I attended the <BIO KOREA 2024> event held at Coex Exhibition Center in Seoul. While the number of attendees hasn't fully recovered to pre-COVID-19 pandemic levels, qualitatively, it was impressive to see the participation of top-notch companies and partners from around the globe. I had pleasant conversations with various #CDMO companies from the United States, Europe, and Asia. Of course, I also exchanged warm greetings with Korean companies. I extend my gratitude to everyone who kindly exchanged business cards with warm greetings. Customers showed a high interest in Quascenta Pte. Ltd.'s offerings like eLogbook, eProcess Pro, and eResidue Pro, which aim to enhance the quality of processes. I believe this warm interest stems from the admirable sense of purpose among CDMO companies striving to deliver better quality to their customers. Personally, rather than solely aiming for sales achievements, I too aspire to take a deeper interest in Quascenta's mission to contribute to the pharmaceutical industry. I respect Ravi Moorthy, the leader of Quascenta, because he believes in integrating our software, knowledge, and experience to deliver more value to customers. #전자로그북 #eLogbook #DataIntegrity #PharmaDigitalization #We_Consider #Quality #Quascenta

globalpharma's 2024 was an incredible journey of orchestrating the rhythm for future success. This video highlights our key moments as we pave the way for a strong 2025. #globalpharma #YearInReview #TeamSuccess #BuildingTheFuture

Following the exciting news that CatSci Ltd have acquired Reach Separations, CatSci CEO, Ross Burn, shares his thoughts: "We are excited to welcome Reach Separations into the CatSci Group. The need for solving complex analytical problems while meeting the ever-evolving regulatory demands is growing alongside the development of new modalities, such as oligonucleotides, TACs (Targeting Chimeras), and glues. Joining forces with Reach gives our customers access to end-to-end coverage of the analytical development lifecycle, taking them from discovery through to GMP manufacture, and ultimately enabling them to help patients in need.’’ More on the acquisition here: https://lnkd.in/d9di7_5n

“Almac Discovery warmly welcomes today’s launch of the Future Medicines Institute (FMI). We are excited to start the journey on this five-year UKRI project and look forward to developing sector-relevant skills, enhancing access to cutting edge equipment and expertise, driving business opportunity and growth and ultimately to seeing direct benefits to patients in NI and beyond.” Dr Stephen Barr, President and Managing Director of Almac Discovery. Read more: https://hubs.li/Q02-nYyD0

Following our recent acquisition of Reach Separations, here’s what Peter Ridgway, Business Development Director at Reach Separations, had to say: "Becoming part of the CatSci Ltd Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces." This strategic acquisition marks a significant milestone for CatSci and enhances our ability to deliver programmes where rapid purification by chromatography is often essential to expediting clinical development. Together with Reach, we will drive forward our shared mission to deliver excellence in medicines development.   Learn more about how this acquisition will solve our customers' separation science challenges: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

Thrilled to attend #DIAEurope2024, where industry leaders converged to explore cutting-edge advancements in healthcare. From insightful discussions to impactful networking, the conference provided an invaluable platform to delve into the future of pharmaceuticals and regulatory affairs. Grateful for the enriching experiences and connections made! #HealthcareInnovation #Regulatory #clinicalresearch #clinicaltrial #gcp #pharmacovigilance #drugdiscovery #drugdevelopment #drugsafety

Thoughts on this? >> BenevolentAI CEO exits after less than a year on the job >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare

Thoughts on this? >> BenevolentAI CEO exits after less than a year on the job >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical

This week, the Lyfegen team will be attending two major events across different continents! From October 9th to 11th, we’ll be at the EPP - Pricing Platform Platform Life Sciences Pricing Forum 2024 in Berlin, the premier event for Pricing, Market Access, and Reimbursement leaders. Our CXO & Founder, Nico Julian Mros, will host the session: “𝗪𝗵𝘆 𝗦𝗮𝘆𝗶𝗻𝗴 ‘𝗜𝘁’𝘀 𝗧𝗼𝗼 𝗗𝗶𝗳𝗳𝗶𝗰𝘂𝗹𝘁’ 𝗡𝗼 𝗟𝗼𝗻𝗴𝗲𝗿 𝗪𝗼𝗿𝗸𝘀 𝗶𝗻 𝗩𝗮𝗹𝘂𝗲-𝗕𝗮𝘀𝗲𝗱 𝗖𝗼𝗻𝘁𝗿𝗮𝗰𝘁𝗶𝗻𝗴.” At the same time, on October 10th, we’ll be in St. John’s, NL, for the NLHS Innovation Summit, where Ina Hasani, MSc, MBA our Director, Sales & Business Development, will lead the session: “𝗙𝗮𝘀𝘁-𝘁𝗿𝗮𝗰𝗸𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗕𝗲𝘁𝘁𝗲𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀.” We’re excited to showcase how Lyfegen is driving growth and sustainability for manufacturers worldwide. Book a demo with us before the events here: https://lnkd.in/dn6Nh7sh. Don’t miss your chance to connect with us in Berlin or St. John’s and discover how we can support your pricing and market access needs. Simon Farrow #LifeSciences #PricingForum #MarketAccess #Pharmaceuticals #MedTech #Biotech #HealthcareInnovation #ReimbursementStrategies #PricingStrategies #SustainabilityInHealthcare #BerlinEvents #Lyfegen #EPPForum #StJohnsEvents

Continuing our Protas People series, this week’s spotlight is on William Hayes, our Drug Supply Manager 💊    William leads in the design and delivery of a drug supply plan that supports Protas’ mission of delivering efficient and impactful trials.    “It is such a privilege to work at a company that is full of people passionate about improving the landscape of clinical trials, where I can see the real-world impact of my work.”    Visit our website to read more about our mission and work: www.protas.co.uk     #ProtasPeople #LifeAtProtas #ClinicalTrials #SupplyChainManagement